Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 1,723.4	$ 1,224.6
Marketable securities	1,228.8	2,313.4
Accounts receivable, net	1,959.6	1,958.5
Due from anti-CD20 therapeutic programs	557.5	526.9
Inventory	776.7	929.9
Assets held for sale	683.4	0.0
Other current assets	980.4	687.6
Total current assets	7,909.8	7,640.9
Marketable securities	1,309.3	1,375.9
Property, plant and equipment, net	3,077.5	3,601.2
Operating lease assets	434.4	0.0
Intangible assets, net	3,681.3	3,120.0
Goodwill	5,749.2	5,706.4
Deferred tax asset	2,820.1	2,153.9
Investments and other assets	1,306.0	1,690.6
Total assets	26,287.6	25,288.9
Current liabilities:
Taxes payable	427.2	63.5
Accounts payable	377.1	370.5
Liabilities held for sale	88.6	0.0
Accrued expenses and other	2,318.0	2,861.2
Total current liabilities	3,210.9	3,295.2
Notes payable	5,948.5	5,936.5
Deferred tax liability	2,400.6	1,636.2
Long-term operating lease liabilities	423.0	0.0
Other long-term liabilities	1,355.8	1,389.4
Total liabilities	13,338.8	12,257.3
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	0.0
Accumulated other comprehensive loss	(252.9)	(240.4)
Retained earnings	16,182.8	16,257.0
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	12,952.9	13,039.6
Noncontrolling interests	(4.1)	(8.0)
Total equity	12,948.8	13,031.6
Total liabilities and equity	$ 26,287.6	$ 25,288.9